193 related articles for article (PubMed ID: 35331717)
1. Merkel Cell Carcinoma Sensitivity to EZH2 Inhibition Is Mediated by SIX1 Derepression.
Gartin AK; Frost TC; Cushman CH; Leeper BA; Gokhale PC; DeCaprio JA
J Invest Dermatol; 2022 Oct; 142(10):2783-2792.e15. PubMed ID: 35331717
[TBL] [Abstract][Full Text] [Related]
2. Distinct Regulation of EZH2 and its Repressive H3K27me3 Mark in Polyomavirus-Positive and -Negative Merkel Cell Carcinoma.
Durand MA; Drouin A; Mouchard A; Durand L; Esnault C; Berthon P; Tallet A; Le Corre Y; Hainaut-Wierzbicka E; Blom A; Saiag P; Beneton N; Bens G; Nardin C; Aubin F; Dinulescu M; Collin C; Fromont-Hankard G; Cribier B; Laurent-Roussel S; Cokelaere K; Houben R; Schrama D; Peixoto P; Hervouet E; Bachiri K; Kantar D; Coyaud E; Guyétant S; Samimi M; Touzé A; Kervarrec T
J Invest Dermatol; 2023 Oct; 143(10):1937-1946.e7. PubMed ID: 37037414
[TBL] [Abstract][Full Text] [Related]
3. Methyltransferase-independent function of enhancer of zeste homologue 2 maintains tumorigenicity induced by human oncogenic papillomavirus and polyomavirus.
Khattri M; Amako Y; Gibbs JR; Collura JL; Arora R; Harold A; Li MY; Harms PW; Ezhkova E; Shuda M
Tumour Virus Res; 2023 Dec; 16():200264. PubMed ID: 37244352
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression of ALK and EZH2 in Merkel cell carcinoma.
Veija T; Koljonen V; Bohling T; Kero M; Knuutila S; Sarhadi VK
BMC Cancer; 2017 Mar; 17(1):236. PubMed ID: 28359267
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive value of EZH2 expression and the tumor immune microenvironment in Merkel cell carcinoma.
Acikalin A; Bagir E; Paydas S
Pol J Pathol; 2021; 72(2):140-147. PubMed ID: 34706521
[TBL] [Abstract][Full Text] [Related]
6. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of EZH2 in Merkel cell carcinoma is associated with disease progression and poorer prognosis.
Harms KL; Chubb H; Zhao L; Fullen DR; Bichakjian CK; Johnson TM; Carskadon S; Palanisamy N; Harms PW
Hum Pathol; 2017 Sep; 67():78-84. PubMed ID: 28739498
[TBL] [Abstract][Full Text] [Related]
8. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
9. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
10. Regulation of cancer stem cell properties by SIX1, a member of the PAX-SIX-EYA-DACH network.
Kingsbury TJ; Kim M; Civin CI
Adv Cancer Res; 2019; 141():1-42. PubMed ID: 30691681
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
[TBL] [Abstract][Full Text] [Related]
12. Polycomb complex mediated epigenetic reprogramming alters TGF-β signaling via a novel EZH2/miR-490/TGIF2 axis thereby inducing migration and EMT potential in glioblastomas.
Vinchure OS; Sharma V; Tabasum S; Ghosh S; Singh RP; Sarkar C; Kulshreshtha R
Int J Cancer; 2019 Sep; 145(5):1254-1269. PubMed ID: 31008529
[TBL] [Abstract][Full Text] [Related]
13. Non-canonical transcriptional regulation of INHAT subunit SET/TAF-Iβ by EZH2.
Hwang IJ; Park J; Seo SB
Biochem Biophys Res Commun; 2022 Dec; 635():136-143. PubMed ID: 36274363
[TBL] [Abstract][Full Text] [Related]
14. The polycomb proteins EZH1 and EZH2 co-regulate chromatin accessibility and nephron progenitor cell lifespan in mice.
Liu H; Hilliard S; Kelly E; Chen CH; Saifudeen Z; El-Dahr SS
J Biol Chem; 2020 Aug; 295(33):11542-11558. PubMed ID: 32554463
[TBL] [Abstract][Full Text] [Related]
15. Polycomb Repressive Complex 2 Proteins EZH1 and EZH2 Regulate Timing of Postnatal Hepatocyte Maturation and Fibrosis by Repressing Genes With Euchromatic Promoters in Mice.
Grindheim JM; Nicetto D; Donahue G; Zaret KS
Gastroenterology; 2019 May; 156(6):1834-1848. PubMed ID: 30689973
[TBL] [Abstract][Full Text] [Related]
16. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.
Wen Y; Cai J; Hou Y; Huang Z; Wang Z
Oncotarget; 2017 Jun; 8(23):37974-37990. PubMed ID: 28415635
[TBL] [Abstract][Full Text] [Related]
17. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
Ler LD; Ghosh S; Chai X; Thike AA; Heng HL; Siew EY; Dey S; Koh LK; Lim JQ; Lim WK; Myint SS; Loh JL; Ong P; Sam XX; Huang D; Lim T; Tan PH; Nagarajan S; Cheng CW; Ho H; Ng LG; Yuen J; Lin PH; Chuang CK; Chang YH; Weng WH; Rozen SG; Tan P; Creasy CL; Pang ST; McCabe MT; Poon SL; Teh BT
Sci Transl Med; 2017 Feb; 9(378):. PubMed ID: 28228601
[TBL] [Abstract][Full Text] [Related]
18. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.
Tiffen JC; Gunatilake D; Gallagher SJ; Gowrishankar K; Heinemann A; Cullinane C; Dutton-Regester K; Pupo GM; Strbenac D; Yang JY; Madore J; Mann GJ; Hayward NK; McArthur GA; Filipp FV; Hersey P
Oncotarget; 2015 Sep; 6(29):27023-36. PubMed ID: 26304929
[TBL] [Abstract][Full Text] [Related]
19. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
Mu W; Starmer J; Yee D; Magnuson T
Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
[TBL] [Abstract][Full Text] [Related]
20. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
